MindWalk Holdings Corp.

MindWalk Holdings Corp. is a Bio-Native AI company focused on transforming drug discovery and development through the integration of artificial intelligence, multi-omics data, and advanced laboratory research. Headquartered in Austin, Texas, the company was founded in 1983 and aims to accelerate the discovery and development of biologics by providing computable, actionable solutions for complex biological problems.

The company's core offerings revolve around its patented HYFT® technology and the LensAI™ platform, which unify sequence, structure, function, and literature into a single computational language. This ecosystem, supported by an integrated wet lab, enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics. MindWalk partners with pharmaceutical and biotechnology companies, offering data-as-a-service (DaaS) and software-as-a-service (SaaS) products, with a focus on therapeutic antibodies, anti-drug antibodies, diagnostics, vaccines, and peptide therapeutics.

Led by CEO Dr. Jennifer Bath, MindWalk Holdings Corp. has recently been active in expanding its technological and market presence. In July 2026, the company filed a European patent application for its high-dimensional biological data architecture, reinforcing its strategy to secure the data layer beneath AI models as a key differentiator. Other recent developments include the launch of its ReefIQ™ biological context layer in June 2026, preclinical data supporting its HYFT® computational predictions for dengue, and the deployment of a Pandemic Response Platform in May 2026. MindWalk Holdings Corp. was also added to the Russell 3000E Index in July 2026.